Reanalysis of TransVax immunogenicity

摘要

Further to the correction to our report of the results of a phase 2 trial of a novel immunotherapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation,1 we thought it necessary to reassess our original analysis so as to examine the strength of evidence for the immunogenicity of the TransVax vaccine. To that end, we propose a more appropriate statistical method for measurement of phosphoprotein 65 (pp65) immunogenicity.